116308-40-8

Upstream product

• 104-10-9 2-(4'-aminophenyl)ethyl alcohol 
• 116308-39-5 2-<4-(1-piperazinyl)phenyl>ethyl alcohol 
• 776-74-9 Bromodiphenylmethane 

Downstream Products

• 116308-41-9 2-<4-(4-benzhydryl-1-piperazinyl)phenyl>ethyl acetoacetate 
• 116308-56-6 AE₀₀₄₇ 
• 134028-04-9 (4S)-(+)-2-<4-(4-Benzhydryl-1-piperazinyl)phenyl>ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate 
• 116308-53-3 2',6'-Dimethyl-2-trifluoromethyl-1',4'-dihydro-[3,4']bipyridinyl-3',5'-dicarboxylic acid 5'-{2-[4-(4-benzhydryl-piperazin-1-yl)-phenyl]-ethyl} ester 3'-methyl ester 
• 116308-51-1 2-<4-(4-benzhydryl-1-piperazinyl)phenyl>ethyl methyl 4-(4-cyano-2-pyridyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylate 
• 133743-70-1 2-[1-(3-Nitro-phenyl)-meth-(Z)-ylidene]-3-oxo-butyric acid 2-[4-(4-benzhydryl-piperazin-1-yl)-phenyl]-ethyl ester 
• 134364-85-5 2-<4-(4-benzhydryl-1-piperazinyl)phenyl>ethyl 2-(4-cyano-2-pyridylmethylidene)acetoacetate 

Relevant academic research and scientific papers

Hydrogenated acridine derivative and its application

The invention relates to the field of chemical synthesis, and particularly relates to a compound with the general formula being Y-L-X and an application of the compound serving as a calcium channel blocking agent or/and an acetylcholinesterase inhibitor. The compound with the general formula being Y-L-X can be used for adjusting calcium homeostasis and treating cardiovascular diseases, stroke or dementia.